Abstract

In our study, we investigated molecular mechanisms of increased adenoviral transduction efficacy in cisplatin-resistant human laryngeal carcinoma cells CA3ST as compared to parental cells HEp2. Using reverse transcription-PCR, the genes potentially implicated in adenoviral entry were screened. In cisplatin-resistant cells, only upregulation of αvβ3 integrin was detected, which was additionally confirmed by flow cytometry. Moderately increased expression of CAR was determined in cisplatin-resistant CA3ST cells using flow cytometry and measurement of wild-type adenovirus Ad5CMVβgal attachment. In order to test the implication of αvβ3 integrin in transduction efficacy, 6 HEp2-derived αvβ3-expressing clones with graded expression of αvβ3 were isolated. To a certain degree of density, expression of αvβ3 positively correlated with Ad5CMVβgal transduction efficacy (i.e., increased viral transduction), suggesting a role of αvβ3 in transduction efficacy. However, HEp2 clones with the highest αvβ3 expression were negatively correlated with transduction efficacy (i.e., decreased viral transduction). This was shown to be associated with downregulation of αvβ5 integrin, also involved in viral transduction, in clones with the highest αvβ3 expression. The implication of CAR in increased adenoviral transduction efficacy in cisplatin resistant CA3ST cells was further assessed by transduction experiments using adenoviral mutant Ad5FbΔ639 whose entry is only to a very small extent dependent on the presence of CAR. Indeed, Ad5FbΔ639 infected 2.5-fold more, in comparison to wild-type adenovirus, which infected 5-fold more efficiently resistant CA3ST cells than parental HEp2 cells, indicating that increased expression of CAR contributes to increased efficacy of adenoviral transduction. Thus, the data presented provide evidence that both αvβ3 integrin and CAR are involved in increased adenoviral transduction efficacy in cisplatin resistant CA3ST cells. These findings may have significant implications in human gene therapy using adenoviruses, especially in patients after unsuccessful cisplatin treatment. © 2004 Wiley-Liss, Inc.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call